Incyte Corp Ltd (INCY): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Incyte ( INCY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.5%. By the end of trading, Incyte rose $1.01 (4.3%) to $24.49 on average volume. Throughout the day, 1.9 million shares of Incyte exchanged hands as compared to its average daily volume of 1.6 million shares. The stock ranged in a price between $23.36-$24.53 after having opened the day at $23.52 as compared to the previous trading day's close of $23.48. Other companies within the Drugs industry that increased today were: iBio ( IBIO), up 15.4%, Amicus Therapeutics ( FOLD), up 8.1%, Sunesis Pharmaceuticals ( SNSS), up 7.4%, and Simcere Pharmaceutical Group ( SCR), up 6.7%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $3.13 billion and is part of the health care sector. Shares are up 40.8% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Incyte a buy, one analyst rates it a sell, and two rate it a hold.

TheStreet Ratings rates Incyte as a sell. Among the areas we feel are negative, one of the most important has been poor profit margins.

On the negative front, Spectrum Pharmaceuticals ( SPPI), down 37.3%, PharmAthene ( PIP), down 9.6%, Oxygen Biotherapeutics ( OXBT), down 9.4%, and Geron Corporation ( GERN), down 9.2%, were all laggards within the drugs industry with Novartis ( NVS) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Cramer: There Should Be More Takeovers Where These Came From

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug

How Competition Drives Stocks Nowhere: Cramer's 'Mad Money' Recap (Tuesday 7/11/17)